LCZ696, Novartis

Drug: LCZ696
Company: Novartis
Phase: Phase III
Class: AT1 receptor-neprilysin (ARNI) inhibitor
2020 sales: $1.3 billion
Net present value: $3.0 billion

Novartis' ($NVS) cardio group was on the ropes, taking a beating for the serelaxin failure when LCZ696 came along to save the day. Seemingly out of nowhere, this drug emerged as a top contender among late-stage heart drugs, potentially worth billions in added sales. EvaluatePharma's estimate qualifies as a conservative forecast, if all goes according to plan. The pharma giant captured the cardiology world's attention when it announced that a pivotal study for the drug had been halted early on based on its success regarding mortality and hospitalizations when compared to the generic Vasotec. With the Diovan franchise about to be chopped up, a win here is needed badly. But heart drugs aren't easily approved, and the pharma giant faces a big challenge in getting this drug through regulators and onto the market.

For more:
Meet the new Novartis: Slimmer structure, same R&D commitment
The EU's not impressed with Novartis' 'breakthrough' cardio drug, either
Analysts, experts are dazzled by the blockbuster potential of Novartis' LCZ696

LCZ696, Novartis
Read more on

Suggested Articles

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.

The bispecific outperformed J&J’s blockbuster against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis,

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.